Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Francesca Bruce

Senior Writer

Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe and is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Pink Sheet, Scrip and In Vivo.

Latest From Francesca Bruce

EU Urban Wastewater Directive Update ‘Unfairly Targets Pharmaceutical Industry’

The European Parliament has voted for a deal agreed with the council of minister to ensure polluters pay for cleaning up urban wastewater.

Europe Germany

EU Urban Wastewater Directive Update ‘Unfairly Targets Pharmaceutical Industry’

The European Parliament has voted for a deal agreed with the council of minister to ensure polluters pay for cleaning up urban wastewater.

Europe Germany

Industry Calls For Caution Over EMA Supply Chain Recommendations

The European Medicines Agency has published guidance on how to strengthen the supply chain for products included on the EU’s critical medicines list.

Europe Ingredients

EU Launches Critical Medicines Alliance But Prospect Of Act On Manufacturing Still Uncertain

Work on safeguarding the medicine supply chain should be accompanied by ambitious actions to ensure the future of the sector, including a new deal on competitiveness, says the pharmaceutical industry.

Europe Policy

Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

Real-world evidence and patient involvement can help developers shore up evidence from single arm trials for EU-wide joint clinical assessments.

Europe Gene Therapy

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Europe Approvals
See All
UsernamePublicRestriction

Register